Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients

This publication has 21 references indexed in Scilit:

• Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
  Journal of Clinical Oncology, 2008
• Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033
  Journal of Clinical Oncology, 2008
• Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors
  Journal of Clinical Oncology, 2006
• Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC–ISG–AGITG)
  European Journal Of Cancer, 2006
• KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
  European Journal Of Cancer, 2006
• Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg
  European Journal Of Cancer, 2005
• Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era
  Cancer, 2005
• Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
  The Lancet, 2004
• Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
  New England Journal of Medicine, 2002
• Regression modelling strategies for improved prognostic prediction
  Statistics in Medicine, 1984